Full-Time

Senior Commercial Data Analyst

Commercial Operations, Oracle TCA

Posted on 7/30/2025

Cooper Companies

Cooper Companies

201-500 employees

Global medical devices and vision care

No salary listed

United Kingdom

Hybrid

Hybrid role; office/home split with onsite presence as required; travel within UK/Europe.

Category
Data & Analytics (2)
,
Required Skills
Python
Data Science
SQL
Excel/Numbers/Sheets
Requirements
  • Oracle EBS or fusion
  • Oracle TCA, Order to Cash modules
  • Excellent data manipulation skills using SQL, Python and Excel
  • Good communication and partnering skills
  • Attention to detail
  • Ability to work accurately in a fast paced environment
  • Good knowledge of key commercial processes
  • Good knowledge of how systems and data support key commercial processes
  • Good analytical and problem solving skills
  • English language - Excellent written and verbal communication skills
  • Knowledge of relevant applications such as Sales Force, eCommerce applications, big data solutions, and data management and linkage tools
  • Bachelor’s degree in information technology related discipline preferred (education)
Responsibilities
  • Provide Oracle OTC and TCA expertise and guidance to the EMEA Region
  • Partner with the EMEA Commercial Systems Lead, Global Commercial Ops team when building new, or enhancing existing, functional requirements that create internal efficiency ir improve the customer Order to delivery experience.
  • Provide a focal point for up to 28 EMEA markets to ensure country data maintenance supports regional and global business process needs.
  • Provide regional expertise and hands-on support when executing changes in the cloud-based Oracle CDM customer mastering tool.
  • Ensure data ServiceNow ticket Service Level Agreements (SLAs) of 48 hours are adhered to.
  • Working with the EMEA Head of Commercial Data, ensure that new customer set-up follows the new customer data set-up process for golden and non-golden data e.g. creation of an account and account relationships, establishing account bill to / ship to relationship.
  • Working with the EMEA Commercial Data Lead ensure that the maintenance of existing customer recordsadheres to global data standards e.g. data to enrich existing customer attributes, managing inactive records, movements of customers to new customer models.
  • Support the region and work with the global team to develop and evolve customer data management including identification of new customer data frameworks that accurately represent the way CooperVision engages with its customers.
  • Additional accountabilities include: maintaining contact data in SalesForce CRM, EMEA data changes to SalesForce Apttus accounts, Customer/Finance data for non-golden set up relating to products and pricing and supporting data governance of distribution data in JDA.
  • Anticipated role breakdown: 60% customer data analysis and management, 20% OTC functional capability review and enhancement, 10% personal development
Desired Qualifications
  • Prior experience/expertise with Customer Master data, Oracle TCA structure, SalesForce (SFDC) and Manufacturing & Distribution using JDA is a plus
  • Experience of data maintenance and analysis in MDM technology (preferably Oracle)
  • Bachelor’s degree in information technology related discipline preferred

Cooper Companies operates in two main areas: CooperVision and CooperSurgical. CooperVision makes a wide range of contact lenses to correct vision, supported by product development, manufacturing, and global distribution. CooperSurgical offers medical devices, fertility, and genomic products for women’s health, covering care from contraception through advanced reproductive treatments, with a vertically integrated model that controls research, development, manufacturing, and distribution. Compared with competitors, the company combines vision care and women’s health in one group and maintains end-to-end control of its product lifecycle, enabling integrated supply and service delivery to healthcare providers and patients worldwide. Its goal is to improve health outcomes for people through accessible contact lenses and comprehensive women’s health products and services, across the globe.

Company Size

201-500

Company Stage

IPO

Headquarters

Pleasanton, California

Founded

1958

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue hit $1.02B, raising FY2026 guidance to $4.31B-$4.35B.
  • Paul Keel joins board July 2026, adding Envista CEO expertise for operations scaling.
  • 18 consecutive years of CooperVision contact lens market share gains through premium portfolio.

What critics are saying

  • Alcon's Total30 lenses erode CooperVision's daily disposable share within 6-12 months.
  • Japan hydrogel decline cuts Asia Pacific revenue 5-7% in 3-6 months.
  • Cook Medical recaptures 10-15% CooperSurgical fertility share via hospital contracts in 12-18 months.

What makes Cooper Companies unique

  • CooperVision leads with MyDay and MiSight premium contact lenses for astigmatism and myopia.
  • CooperSurgical offers vertically integrated fertility genomics and women's health devices.
  • Dual-segment model separates vision care from reproductive health for focused innovation.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

Performance Bonus

Health Insurance

401(k) Retirement Plan

Life Insurance

Wellness Program

Professional Development Budget

Company News

Oregon Capital Insider
May 4th, 2026
CooperCompanies appoints Paul Keel to its Board of Directors.

CooperCompanies appoints Paul Keel to its Board of Directors. GlobeNewswire | CooperCompanies Yesterday at 1:15pm PDT SAN RAMON, Calif., May 04, 2026 (GLOBE NEWSWIRE) - CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today that its Board of Directors has appointed Paul Keel as an independent director, effective July 1, 2026. Mr. Keel has also been appointed to serve on the Audit Committee when he joins the Board. "We are delighted to welcome Paul to our Board as a new Director," said Colleen Jay, Chair of the Board of CooperCompanies. "His experience as a CEO in the medical device sector, along with a successful track record of leading complex global operations, will be a significant asset as Cooper continues to execute its strategy and create long-term value for patients, customers, and shareholders." Mr. Keel has served as President and Chief Executive Officer of Envista Holdings Corporation (NYSE: NVST), a global specialty medical technology company, since 2024. Prior to joining Envista, Mr. Keel served as CEO of Smiths Group plc (LON: SMIN), a diversified global industrial technology company and FTSE constituent, from 2021 to 2024. Earlier, he spent 16 years at 3M, serving in various leadership roles, including Group President of 3M Consumer Business, President of 3M Medical, President of 3M Unitek, SVP of Manufacturing & Supply Chain, and SVP of Marketing, Sales & Business Development. Mr. Keel's career also includes roles at General Mills, General Electric, Norwest Equity Partners, and McKinsey & Company. He holds an MBA from Harvard Business School and a BA in Economics from Carleton College. About CooperCompanies CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women's healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com. Forward-Looking Statements This press release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to the Company's efforts to enhance long-term shareholder value, plans, strategies, future actions, and other statements of which are other than statements of historical fact, are forward-looking. Forward-looking statements necessarily depend on assumptions, data, or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Statements regarding future events and performance and contain words such as "expects" and similar words or phrases. A wide range of factors could materially affect future developments, including, but not limited to, uncertainties related to market conditions and other factors set forth in its other filings with the United States Securities and Exchange Commission, including its most recent Annual Report on Form 10-K. These risks and uncertainties may cause actual future results or actions to be materially different than those expressed in such forward-looking statements. Oregon Capital Insider do not intend, or undertake any duty, to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Kim Duncan Vice President, Investor Relations and Risk Management 925-460-3663 This is a paid placement. For further inquiries, please contact GlobeNewswire directly.

Yahoo Finance
Apr 8th, 2026
Cooper Companies shares drop 17% in 3 months amid valuation debate at $13.7B market cap

Cooper Companies has raised $120 million in a Series C round, valuing the healthcare company at $1.45 billion, as shares face recent pressure with declines of 9% over the past month and roughly 17% over three months. The company operates two main businesses: CooperVision, generating revenue of $2.79 billion from contact lenses, and CooperSurgical, contributing $1.36 billion from women's and family health products. Total annual revenue reached $4.15 billion with net income of $401.4 million. Recent analysis suggests the stock may be 24.1% undervalued at its current price of $69.66, with a fair value estimate of $91.80. Management projects approximately $2 billion in free cash flow over the next three years as capital expenditure cycles wind down.

Yahoo Finance
Mar 25th, 2026
CooperCompanies Q4 revenue hits $1.02B, raises full-year earnings guidance

CooperCompanies reported Q4 revenues of $1.02 billion, up 6.2% year on year, meeting analysts' expectations. The medical devices manufacturer, which focuses on vision care and women's health products, delivered an impressive beat on full-year earnings per share guidance, though organic revenue was in line with estimates. The company raised both earnings and free cash flow guidance following strong profitability and cash generation. Operating margins exceeded expectations due to synergies from last year's reorganisation. President and CEO Al White highlighted momentum from product launches, including the premium MyDay portfolio and early traction from MyDay MiSight. Across the medical devices and supplies sector, six tracked companies reported mixed Q4 results, with revenues collectively beating consensus estimates by 1.9%. Share prices have declined 9.5% on average since earnings announcements.

Yahoo Finance
Mar 17th, 2026
Cooper Companies down 21% from 52-week high despite beating Q1 earnings estimates

Cooper Companies, a California-based medical devices manufacturer, has declined 12.5% over the past 52 weeks, underperforming the Dow Jones Industrial Average's 13.2% gain during the same period. The company, valued at $13.9 billion, has fallen 20.9% from its December 2025 peak of $89.83. Shares dropped 2.2% on 5 March following mixed Q1 2026 results. Whilst revenue rose 6% year-over-year to $1 billion and adjusted earnings per share increased 20% to $1.10, both beating estimates, investors focussed on weak organic revenue growth and challenges in the Asia Pacific region. The stock has traded below its 200-day and 50-day moving averages since early March. Despite the decline, analysts maintain a "Moderate Buy" rating with a mean price target of $90.81, suggesting 27.8% upside potential.

Yahoo Finance
Mar 12th, 2026
Needham raises Cooper Companies price target to $101, maintains buy rating after strong Q1 results

Needham raised its price target on The Cooper Companies (NASDAQ: COO) to $101 from $99, maintaining a Buy rating. The firm cited solid first-quarter results, improving end markets and operating efficiencies supporting margin expansion. Barclays also increased its target to $103 from $98 with an Overweight rating, noting improving sequential growth in Vision and Surgical segments offsetting declines in older hydrogel products in Japan. Cooper Companies reported first-quarter non-GAAP earnings per share of $1.10, beating the $1.03 consensus estimate, with revenue of $1.024 billion versus $1.02 billion expected. CEO Al White highlighted growth in the MyDay portfolio and benefits from last year's reorganisation. The company develops and markets products for contact lens wearers through its CooperVision and CooperSurgical segments.

INACTIVE